Ibogaine treatment for alcohol use disorder works differently from ibogaine treatment for opioid dependence — and the distinction matters before you begin. The mechanism overlaps, but the preparation requirements do not. Alcohol withdrawal is medically dangerous in a way opioid withdrawal typically is not. You cannot enter an ibogaine ceremony in active alcohol withdrawal. And heavy, chronic alcohol use frequently produces hepatic damage that changes how ibogaine is metabolised. Both issues must be resolved before any ceremony is appropriate.
Ibogaine treatment for alcohol is a legitimate therapeutic option with a growing evidence base. In Canada it costs $2,000–$5,000 CAD, requires medical alcohol detox before ceremony, and is not appropriate for people with compromised liver function, QT prolongation, current SSRI or SNRI use, or several other conditions. The screening conversation is where candidacy is established — not after you have already arranged to attend.
How ibogaine addresses alcohol addiction
Alcohol use disorder and opioid use disorder share a neurological layer — the dopamine reward pathway, depleted over time by chronic substance use. Ibogaine's primary mechanism relevant to addiction is GDNF upregulation: glial cell line-derived neurotrophic factor, a neuroplasticity protein that becomes depleted in the dopaminergic pathways affected by long-term substance dependence. Research has documented this effect most clearly in opioid-affected pathways, but the mechanism is not specific to opioids.
Ibogaine also acts as an NMDA antagonist, inhibits the serotonin transporter, and resets mu-opioid receptor sensitivity. For opioid dependence, that last mechanism produces a direct withdrawal interruption — ibogaine essentially resets receptor occupancy. Alcohol does not act through opioid receptors in the same way. The reset is less direct. What ibogaine offers for alcohol is primarily the GDNF effect — the weeks-long neuroplasticity window that follows ceremony — combined with the biographical confrontation the experience produces. Craving reduction in the days to weeks following ibogaine ceremony has been observed clinically; the mechanism is plausible even where the alcohol-specific RCT data does not yet exist.
This is the honest picture. The evidence for ibogaine in opioid dependence is stronger than the evidence for ibogaine in alcohol dependence. That does not mean ibogaine is not useful for alcohol — it means the research has not caught up to what practitioners have been observing. What the research does show is consistent in direction.
What the evidence shows
The 2023 Stanford study published in Nature Medicine examined 30 special operations veterans with PTSD, traumatic brain injury, and treatment-resistant depression — most of whom had significant substance use histories. One month after a single ibogaine treatment: PTSD symptoms decreased by an average of 88%. Depression decreased by 87%. Anxiety by 81%. The population was not primarily defined by alcohol dependence, but substance use was central to the picture. The results were not incremental.
Conventional antidepressant research considers a 50% reduction in depression scores a strong response. These numbers are unusual. The methodological limitations are real — 30 participants, no placebo arm — and should be stated alongside the numbers. Texas subsequently committed $50 million USD to clinical ibogaine trials at four institutions: UTMB, UTHealth Houston, Texas A&M, and Baylor. The direction of the evidence is consistent.
For alcohol specifically: a 2017 observational study by Brown and Alper published in the American Journal of Drug and Alcohol Abuse documented ibogaine treatment outcomes in a mixed-use population. Among those with alcohol dependence, a meaningful proportion reported sustained abstinence at follow-up. The study was observational, not controlled. The MAPS ibogaine research overview tracks the developing evidence base. What the research consistently shows is that ibogaine opens a neuroplasticity window that does not produce lasting change on its own. What is done in that window — the integration period — determines the outcome.
Why alcohol detox must come first
This is not optional, and it is not negotiable: you cannot enter an ibogaine ceremony in active alcohol withdrawal. Alcohol withdrawal produces seizures in a subset of patients — specifically those who have been drinking heavily for years and stop abruptly. The mechanism is neurological: chronic alcohol suppresses GABA and excites glutamate; when alcohol is removed, the resulting glutamate surge can trigger seizure activity. That process does not pause for ibogaine ceremony.
Ibogaine itself is not a benzodiazepine, does not suppress GABA rebound, and does not interrupt alcohol withdrawal seizure risk. A person entering ibogaine ceremony with active alcohol withdrawal exposure is not safer because ibogaine is present. The withdrawal process must be completed — under medical supervision — before any ceremony date is appropriate.
The standard supervised detox protocol is typically 5–7 days. Benzodiazepines are used to manage withdrawal safely. After the detox period is complete and the person is medically stable, the timeline to ibogaine ceremony can be determined — usually a minimum of several weeks after the detox has concluded, to allow the body to stabilise and for screening to be conducted without detox-related variables. Providers who do not ask about current alcohol use and recent drinking history are not conducting adequate screening.
The full preparation timeline for someone actively drinking is therefore longer than for someone already abstinent. If you are currently drinking daily and are planning to pursue ibogaine treatment, the first step is medically supervised alcohol detox — not ceremony application. The full ibogaine ceremony guide covers the general preparation requirements.
Liver function and ibogaine metabolism
Ibogaine is metabolised in the liver, primarily via the CYP2D6 enzyme. Chronic, heavy alcohol use causes hepatic damage — a spectrum from fatty liver (reversible) to alcoholic hepatitis (partially reversible) to cirrhosis (not reversible). The degree of liver damage affects how ibogaine is processed, how long it remains active, and what risk the ceremony produces.
Severe liver disease is an absolute contraindication for ibogaine. This is not a borderline call — it is a hard disqualifier. Compromised hepatic metabolism means ibogaine and its metabolite noribogaine remain in the body for longer, unpredictably extending the active experience and increasing cardiac exposure. The EKG screening that identifies QT prolongation matters less if the metabolism of the compound cannot be predicted.
The pre-ceremony blood panel for anyone with significant alcohol history must include liver function tests: ALT, AST, GGT, and bilirubin at minimum. The results, reviewed by a physician, determine whether ibogaine is safe to administer at any dose. For someone with elevated liver enzymes reflecting active inflammation — as opposed to stable, resolved hepatic history — the ceremony must wait until function has normalised. This may take months of abstinence.
The screening conversation that ends in "not yet" is one of the most important things a legitimate provider does. It is not a failure of the application process — it is the process working correctly. Someone with significant hepatic involvement who wants ibogaine treatment for alcohol is not permanently disqualified in most cases. They are disqualified until the liver function profile allows safe metabolism. The timeline varies; the determination is medical, not arbitrary.
For the full screening picture, the guide to ibogaine treatment in Canada covers what each element of the blood panel and EKG addresses.
What medical screening covers for AUD
The standard ibogaine medical screening applies to everyone regardless of substance history. For someone presenting with alcohol use disorder, several elements carry additional weight:
- EKG and cardiovascular assessment. Ibogaine extends the QT interval. QT prolongation is the primary cardiac contraindication. The EKG establishes baseline, and the cardiovascular assessment identifies any relevant cardiac history. Chronic heavy alcohol use can produce alcoholic cardiomyopathy — cardiac muscle damage from long-term ethanol toxicity. This must be identified before ceremony.
- Liver function panel. ALT, AST, GGT, bilirubin, and albumin. The results determine whether ibogaine can be metabolised safely. Values significantly above normal are a contraindication until resolved.
- Thiamine status and general nutritional assessment.Chronic alcohol use is associated with thiamine deficiency; severe deficiency causes Wernicke's encephalopathy. A legitimate provider screens for this and addresses it before ceremony.
- Full medication history. Benzodiazepines used during alcohol detox must be fully cleared before ibogaine ceremony — the combination is not safe. The clearance window depends on the specific benzodiazepine and duration of use.
- Psychiatric history. Alcohol use disorder and depression co-occur at high rates. Current SSRIs or SNRIs are absolute contraindications for ibogaine — not a preference, but a hard medical contraindication. If antidepressants are being used alongside alcohol, a supervised taper is required before any ceremony date can be confirmed.
The screening does not happen the day of ceremony. It happens weeks in advance. No legitimate provider confirms a ceremony date before the screening results have been reviewed and candidacy established.
Who should not apply
The absolute contraindications apply regardless of substance history. For someone pursuing ibogaine treatment for alcohol specifically, the most common reasons an application results in a no — or a "not yet" — are:
- Active alcohol dependence without completed medically supervised detox. You cannot enter ceremony while still in the physiological withdrawal period. This is a safety issue, not a formality.
- Significantly elevated liver enzymes reflecting active hepatic damage. Severe liver disease is an absolute contraindication. Elevated-but-improving enzyme levels require reassessment at a later date.
- QT prolongation on EKG. Identified before ceremony. Ibogaine extends the QT interval; QT prolongation preceding ibogaine creates serious arrhythmia risk.
- Current SSRIs or SNRIs without a completed supervised taper. The most common reason applications stall — because SSRIs are the standard treatment for depression, which frequently co-occurs with AUD. A supervised taper is required, not optional.
- Benzodiazepines still clearing post-detox. The detox window must close fully before ibogaine is administered. Clearance time depends on the specific medication.
- Acute psychiatric instability. Someone in acute crisis is not an appropriate candidate at that time. The experience amplifies what is present. Instability entering ceremony does not resolve during it.
- Pregnancy.
Some of these are permanent disqualifiers. Others are temporary — the situation requiring preparation rather than a definitive no. The screening conversation establishes which applies. If you want to understand the full contraindication list in detail, the guide to ibogaine for alcohol addiction covers the mechanism and evidence in depth.
What an ibogaine treatment programme involves
At Transcend in Vancouver, BC, ibogaine treatment for alcohol use disorder involves the following:
Intake and screening. An application, a screening conversation, and submission of medical records including EKG results and blood panel. This happens before any date is confirmed or deposit discussed. Every application receives a personal response within 2–3 business days. Applications from people who are clearly not appropriate candidates receive the same response — directly and without softening it. We would rather lose a potential participant than put someone at risk.
Preparation. Once candidacy is confirmed, a preparation period begins: facilitation conversations, intention work, and any outstanding medical requirements. The facilitation conversation addresses what you are bringing to ceremony and what you are hoping to encounter, so that the 12–24 hours of active experience are not the first time these questions are raised.
Ceremony.The active experience lasts 12–24 hours. An on-site medical professional is present throughout. Continuous cardiac ECG monitoring runs for the full duration. The content is typically biographical — a review of one's life and patterns with a quality of emotional neutrality that is different from the charged recollection these memories ordinarily produce. The experience is physically demanding: ataxia, nausea, light and sound sensitivity, inability to sleep. It does not resemble short-duration compounds. People are consistently surprised by the duration and the directness of what the medicine shows them.
Recovery. 2–3 days of supervised recovery on-site. The transition back to ordinary functioning is gradual. Travel is not appropriate on the day of ceremony. The recovery period is not afterthought — it is part of the programme.
Costs. Iboga ceremony at Transcend costs $2,000–$5,000 CAD. This covers the on-site medical professional, continuous cardiac ECG monitoring, whole-plant root bark, facilitation, and 2–3 days of supervised recovery. Integration coaching — $150–$300 CAD per session — is a separate service. Providers charging significantly below this range are not being generous. The cost of a physician present throughout a 12–24 hour ceremony is real. Removing that cost means removing that physician.
The integration period
After ceremony, ibogaine converts to noribogaine in the body. Noribogaine remains biologically active for weeks to months — the most plausible explanation for why ibogaine's effects persist long beyond the active experience. During this window, the nervous system is in a state of elevated plasticity. Existing patterns are more malleable. New ones are more accessible. This is the window in which integration work determines whether anything lasting changes.
The people who see the least durable results from ibogaine treatment for alcohol are the ones who return immediately to the environment, relationships, and unaddressed material that produced the dependence. The ceremony opens the window. The window does not stay open indefinitely. What is done in that window — structured integration support, changes to environment and relationships, engagement with what the experience showed — is what determines the outcome.
Providers who hand people a pamphlet and wish them luck after ceremony are not providing ibogaine treatment. They are providing ibogaine. The integration period is not a bonus service. It is the part that most directly determines whether the neuroplasticity window produces lasting change or closes without one.
If you are considering ibogaine treatment for alcohol use disorder and are ready to begin the screening process, the application starts here. No ceremony date is confirmed before medical screening establishes candidacy.
Frequently Asked Questions
Does ibogaine work for alcohol addiction?
Yes, with caveats. The evidence base for ibogaine in alcohol use disorder is smaller than for opioid dependence, but the direction is consistent. Clinical observations document craving reduction and periods of abstinence following ibogaine ceremony. The 2023 Stanford Nature Medicine study in 30 veterans — who had significant substance use histories — found 88% reductions in PTSD symptoms and 87% reductions in depression at one month. Ibogaine does not cure alcohol dependence. It opens a neuroplasticity window during which sustained change is more accessible. What is done in that window determines the outcome.
Do I need to detox from alcohol before ibogaine?
Yes. Alcohol withdrawal produces seizures in a subset of patients who stop abruptly after chronic heavy use. Ibogaine does not interrupt that process. A medically supervised detox — typically 5–7 days using benzodiazepines to manage withdrawal — must be completed before any ceremony is appropriate. The detox medications must also fully clear before ibogaine is administered. There is no version of ibogaine treatment for alcohol that begins without this step being completed.
How much does ibogaine treatment for alcohol cost in Canada?
Iboga ceremony at Transcend in Vancouver, BC costs $2,000–$5,000 CAD. This covers the on-site medical professional throughout the 12–24 hour active experience, continuous cardiac ECG monitoring, whole-plant root bark, facilitation, and 2–3 days of supervised recovery. Integration coaching — $150–$300 CAD per session — is a separate service. Providers offering ceremonies at significantly lower prices are removing safety infrastructure, not being generous. The cost of a physician present for 12–24 hours is real.
Who cannot do ibogaine treatment for alcohol addiction?
Absolute contraindications include: active alcohol dependence without completed medically supervised detox; significantly compromised liver function (severe liver disease is a hard contraindication); QT prolongation or significant cardiac arrhythmia on EKG; current SSRIs or SNRIs without a completed supervised taper; benzodiazepines not yet cleared post-detox; active psychosis or schizophrenia-spectrum disorder; lithium; pregnancy; and acute psychiatric instability. Some disqualifiers are temporary — the situation requiring preparation. Others are permanent. Medical screening establishes which applies.
Is ibogaine treatment for alcohol available in the United States?
No. Ibogaine has been Schedule I under US federal law since 1970. No provider can legally administer it anywhere in the United States. The nearest legal access for most North Americans is Vancouver, BC — not listed under Canada's Controlled Drugs and Substances Act — 45 minutes north of the Washington State border. Vancouver is a direct flight from most US cities and approximately 2.5 hours from Seattle-Tacoma International Airport.
What does liver damage from alcohol do to ibogaine treatment?
Ibogaine is metabolised hepatically via the CYP2D6 enzyme. Liver damage from chronic alcohol use — from fatty liver to alcoholic hepatitis to cirrhosis — impairs that metabolism, extending ibogaine's active duration unpredictably and increasing cardiac exposure. Severe liver disease is an absolute contraindication. Elevated liver enzymes reflecting active inflammation require resolution before ibogaine is safe to administer. The pre-ceremony blood panel — specifically liver function tests — establishes where the person falls. For many people with significant alcohol history, a period of abstinence is required before enzyme levels normalise enough to allow safe treatment.
How long does an ibogaine programme take for someone with alcohol use disorder?
If you are currently drinking daily, the total preparation timeline is longer than for someone already abstinent. Supervised alcohol detox (5–7 days), detox medication clearance, liver function normalisation, medical screening, and preparation work can add up to 4–8 weeks of preparation before ceremony is appropriate. The on-site programme itself is 5–7 days: preparation day, ceremony day (12–24 hour active experience), 2–3 days of supervised recovery, and an initial integration session before departure.
Does integration support matter more for alcohol than for opioid dependence?
Not more — differently. Alcohol use disorder frequently co-occurs with depression, anxiety, and unresolved trauma. Ibogaine addresses the neurological substrate of the dependence. The integration period — the weeks of elevated neuroplasticity following ceremony — is when the psychological and relational material that sustains the dependence can be engaged most effectively. Returning to an unchanged environment without integration support tends to produce relapse regardless of what the ceremony produced. This applies to all substance dependence treated with ibogaine, but the co-occurring conditions common in AUD make the integration period particularly consequential.